Physiochemical properties of drugs Some background to the Sirius T3.

Slides:



Advertisements
Similar presentations
1 Real World Chemistry Virtual discovery for the real world Joe Mernagh 19 May 2005.
Advertisements

The Drug Discovery Process
D9 – Drug Design (HL). D.9.1 Discuss the use of a compound library in drug design  Over the years, molecules of various substances have been isolated.
Producing a Pharmaceutical or Biopharmaceutical
PhysChem Forum, 29 Nov 2006, Newhouse 1 Memories and the future: From experimental to in silico physical chemistry Han van de Waterbeemd AstraZeneca, DMPK.
Modern Tools for Drug Discovery NIMBUS Biotechnology Modern Tools for Drug Discovery
Improving Candidate Quality Through the Prediction of Clinical Outcome.
Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative.
Software Processes Coherent sets of activities for specifying, designing, implementing and testing software systems.
Ionization and dissociation of drugs-1
Lipinski’s rule of five
1 Title of the paper * Your name *Precise reference for the paper.
Pharmaceutical Analysis Dr. Wael Abu Dayyih Group (3)
Solubility and Dissolution Pharmaceutical Technology.
Doug Brutlag 2011 Genomics, Bioinformatics & Medicine Drug Development
©Ian Sommerville 2004Software Engineering, 7th edition. Chapter 2 Slide 1 Systems engineering 1.
Drug-Like Properties: Optimizing Pharmacokinetics and Safety During Drug Discovery Li Di and Edward H. Kerns ACS Short Course.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Drug discovery and development
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
ERT 420 BIOPHARMACEUTICAL ENGINEERING Semester 1 Academic Session 2012/2013 HUZAIRY HASSAN School Of Bioprocess Engineering Universiti Malaysia Perlis.
Daniel Brown. D9.1 Discuss the use of a compound library in drug design. Traditionally, a large collection of related compounds are synthesized individually.
D9 Drug design Compound libraries Combinatorial and parallel chemistry
Exploratory IND Studies
Functional groups / Pharmacological Activity
A New Oklahoma Bioinformatics Company. Microarray and Bioinformatics.
PHARMACOLOGY oScience of drugs oGreek words= pharmakon (drug) and logos (study) oDeals with interaction of exogenously administered chemical molecules.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 1 A Brief History.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Biopharmaceutics refers to the relationship of the:
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Bioequivalence Dr Mohammad Issa Saleh.
ECCR Overview/MLSCN. NIH Roadmap Series of initiatives designed to pursue major opportunities in biomedical research and gaps in current knowledge that.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
CHEMISTRY NOVEMBER/DECEMBER 2015 Unit 5: Atomic Structure and Nuclear Chemistry.
“Journey of a Drug” From Test Tube TO Prescribing Physician.
Exact PK Equivalence for a bridging study Steven Novick, Harry Yang (MedImmune) and Xiang Zhang (NC State) NCB, October 2015.
Dr. Muslim Suardi, MSi., Apt. Faculty of Pharmacy, University of Andalas.
Background. For designing, discovering or developing a therapeutically relevant molecule, potency and selectivity to the target.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Pharmacology I BMS 242 Lecture 4 Pharmacokienetic Principles (3&4): Drug Metabolism and Excretion [Elimination] Dr. Aya M. Serry 2016.
Physiochemical properties of drugs Using the Sirius T3 to make measurements.
Chapter 1: The Nature of Analytical Chemistry
Reaxys – The Highlights. Slide 2 What is Reaxys? A brand new workflow solution for research chemists and scientists from related disciplines An extensive.
Advantages of Good Drug-like Properties 손한표.
ADME Dr Basma Damiri Toxicology In general, a toxicant should be absorbed in order to have an effect. True or false? Why? False Some toxicants.
Definitions and Concepts
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Lipinski’s rule of five
Group 2 – Nabilah (Presenter), Soonguan, Jingkai
Drug Discovery &Development
Producing a Pharmaceutical or Biopharmaceutical
Introduction of Biopharmaceutics & Pharmacokinetics
Biopharmaceutics of modified release drug products
Figure 1. Biotechnology sector’s knowledge base
Chapter 1 Introduction to Biopharmaceutics & Pharmacokinetics
WHO Technical Report Series, No. 953, 2009
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
ADME/Tox PredictionTox Prediction. The characterization of Absorption, Distribution, Metabolism, and Excretion (also known as ADME) and Toxicity are essential.
Acidity and basicity of Drugs Pharmaceutical Medicinal Chemistry-I
Investigation 4 October 6, 2014
Virtual Screening.
Lixia Yao, James A. Evans, Andrey Rzhetsky  Trends in Biotechnology 
Chapter 1 Introduction of Pharmacology [,fɑ:mə'kɔlədʒi] 药理学
Producing a Pharmaceutical or Biopharmaceutical
Clinical Pharmacokinetics
Producing a Pharmaceutical or Biopharmaceutical
Considerations for Successful Biopharmaceutical Product Development: Discovery to Proof of Concept -A Panel Discussion Stanley C. McDermott, PharmD, MS,
Presentation transcript:

Physiochemical properties of drugs Some background to the Sirius T3

LADMET and drug discovery and development The following extract is taken from an article by Dr Jianling Wang and Dr Laszlo Urban in Drug Discovery World (2004). The increased costs in the discovery and development of new drugs, due in part to the high attrition rate of drug candidates in development, has led to a new strategy to introduce early, parallel evaluation of efficacy and biopharmaceutical properties of drug candidates. Investigation of terminated projects revealed that the primary cause for drug failure in the development phase was the poor pharmacokinetic and ADMET (Absorption, Distribution, Metabolism, Discretion and Toxicity) properties rather than unsatisfactory efficacy. In addition, the applications of parallel synthesis and combinatory chemistry to expedite lead finding and lead optimisation processes has shifted the chemical libraries towards poorer biopharmaceutical properties. Establishments of high throughput and fast ADMET profiling assays allow for the prioritisation of leads or drug candidates by their biopharmaceutical properties in parallel with optimisation of their efficacy at early discovery phases. This is expected to not only improve the overall quality of drug candidates and therefore the probability of their success, but also shorten the drug discovery and development process. Physiochemical properties of drugs

An opportunity Measurement of the physiochemical properties of drugs has always been important, but high throughput and fast ADME profiling has become increasingly important as scientists seek ways of shortening the drug discovery and development process. In this short video sequence John Cromer, Chief Scientific Officer at Sirius Analytical, describes where the need or an instrument that determined pK a values came from and how this led to the development of the T3. Physiochemical properties of drugs Reminder:LADME are the stages that happen when a medicinal drug is taken (usually in a formulation): Liberation – Absorption – Distribution – Metabolism – Excretion The development, construction and use of the T3 brought together aspects of chemistry, engineering, technology, mathematics and computer programming. On the next slide john describes what it can do.

The Sirius T3 The Sirius T3 can determine a number of physiochemical properties that influence the potential of a compound to be a medicinal drug. The four most important ones are: acid dissociation constant, K a, and pK a; partition coefficient, P, and logP; solubility, s, and logs; dissolution. These are important in two main areas of research and development: drug discovery, drug formulation. Physiochemical properties of drugs Reminder:The solubility, dissolution rate, ionisation (pK a ) and lipophilicity (logP) of a drug have a significant effect on its LADME properties.

Making the T3 The Sirius T3 consist of over 5000 parts. These are manufactured around the world and brought to the UK where they are assembled in the Sirius workshops. The software that controls the robot and that carries out the complex mathematical calculations is written at Sirius. Once assembled an instrument is tested for about two weeks using standard samples (substances whose characteristics are well established). Following successful testing it is packaged and shipped to the purchaser. Physiochemical properties of drugs